SG11202103097QA - Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy - Google Patents

Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy

Info

Publication number
SG11202103097QA
SG11202103097QA SG11202103097QA SG11202103097QA SG11202103097QA SG 11202103097Q A SG11202103097Q A SG 11202103097QA SG 11202103097Q A SG11202103097Q A SG 11202103097QA SG 11202103097Q A SG11202103097Q A SG 11202103097QA SG 11202103097Q A SG11202103097Q A SG 11202103097QA
Authority
SG
Singapore
Prior art keywords
cancer therapy
combination
pharmaceutical composition
vaccinia virus
immune checkpoint
Prior art date
Application number
SG11202103097QA
Other languages
English (en)
Inventor
Shinsuke Nakao
Tatsuya Kawase
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of SG11202103097QA publication Critical patent/SG11202103097QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
SG11202103097QA 2018-09-26 2019-09-25 Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy SG11202103097QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018179632 2018-09-26
PCT/JP2019/037448 WO2020067085A1 (ja) 2018-09-26 2019-09-25 腫瘍溶解性ワクシニアウイルスと免疫チェックポイント阻害剤との併用によるがん療法並びにこれに用いるための医薬組成物及び組合せ医薬

Publications (1)

Publication Number Publication Date
SG11202103097QA true SG11202103097QA (en) 2021-04-29

Family

ID=69949634

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103097QA SG11202103097QA (en) 2018-09-26 2019-09-25 Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy

Country Status (13)

Country Link
US (1) US11638730B2 (zh)
EP (1) EP3858369A4 (zh)
KR (1) KR20210065976A (zh)
CN (1) CN112739360A (zh)
AU (1) AU2019351255A1 (zh)
BR (1) BR112021005803A2 (zh)
CA (1) CA3113965A1 (zh)
IL (1) IL281730A (zh)
JO (1) JOP20210051A1 (zh)
MX (1) MX2021003539A (zh)
SG (1) SG11202103097QA (zh)
TW (1) TWI824020B (zh)
WO (1) WO2020067085A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4249596A1 (en) * 2020-11-17 2023-09-27 National University Corporation Tottori University New gene recombinant vaccinia virus and utilization thereof
AU2022358966A1 (en) 2021-10-04 2024-05-02 Tilt Biotherapeutics Oy An oncolytic virus vector coding for interleukin-7 (il-7) polypeptide
WO2024023740A1 (en) * 2022-07-27 2024-02-01 Astrazeneca Ab Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
WO2001028583A2 (en) 1999-10-18 2001-04-26 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
AU779325B2 (en) 1999-10-18 2005-01-20 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
KR20020010206A (ko) 2000-07-27 2002-02-04 이시우 인터루킨 12와 보조활성인자 ｂ7.1 유전자를 함유하는ｄｎａ 벡터 및 이벡터가 도입된 항암 세포백신
CA2818693C (en) 2002-08-12 2016-05-17 Jennerex, Inc. Methods and compositions concerning poxviruses and cancer
US20080050808A1 (en) 2002-10-09 2008-02-28 Reed Thomas D DNA modular cloning vector plasmids and methods for their use
BRPI0411526A (pt) 2003-06-18 2006-08-01 Genelux Corp vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos
US20070036758A1 (en) 2003-07-08 2007-02-15 Bertram Jacobs Mutants of vaccinia virus as oncolytic agents
US7790445B2 (en) 2003-07-21 2010-09-07 Transgene S.A. Polypeptide having an improved cytosine deaminase activity
EP1518932A1 (en) 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Modified vaccinia virus Ankara (MVA) mutant and use thereof
US7638132B2 (en) 2003-12-05 2009-12-29 National University Corporation Hokkaido University Highly safe smallpox vaccine virus and vaccinia virus vector
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
US20070077231A1 (en) 2005-09-30 2007-04-05 Contag Christopher H Immune effector cells pre-infected with oncolytic virus
US8052968B2 (en) 2006-10-16 2011-11-08 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
US8765462B2 (en) 2007-05-04 2014-07-01 University Health Network IL-12 immunotherapy for cancer
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
JP2013527753A (ja) 2010-03-23 2013-07-04 イントレキソン コーポレーション 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用
US20130071430A1 (en) 2010-04-09 2013-03-21 The University Of Tokyo Microrna-controlled recombinant vaccinia virus and use thereof
JPWO2012053646A1 (ja) 2010-10-22 2014-02-24 国立大学法人北海道大学 ワクシニアウイルスベクターおよびセンダイウイルスベクターからなるプライム／ブーストワクチン用ウイルスベクター
WO2012151272A2 (en) 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
KR102277469B1 (ko) 2011-12-12 2021-07-15 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 il-12 유전적 컨스트럭트 및 백신을 포함하는 조성물, 면역치료제 및 이를 이용하는 방법
WO2015069571A1 (en) * 2013-11-05 2015-05-14 Bavarian Nordic, Inc. Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor
CA2931294C (en) 2013-11-21 2022-05-31 National University Corporation Tottori University Mitogen-activated protein kinase-dependent recombinant vaccinia virus (md-rvv) and use thereof
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
ES2703826T3 (es) 2014-02-19 2019-03-12 Merck Patent Gmbh Inmunoterapia con IL-12 destinada al cáncer
ES2770684T3 (es) 2014-03-14 2020-07-02 Novartis Ag Moléculas de anticuerpos contra LAG-3 y usos de los mismos
GB201405834D0 (en) 2014-04-01 2014-05-14 Univ London Queen Mary Oncolytic virus
MA41867A (fr) 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
WO2016205429A1 (en) 2015-06-15 2016-12-22 New York University Method of treatment using oncolytic viruses
EP3313882B1 (en) 2015-06-24 2020-03-11 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
WO2017059095A1 (en) 2015-10-01 2017-04-06 Potenza Therapeutics, Inc. Anti-tigit antigen-binding proteins and methods of use thereof
JP2018532810A (ja) * 2015-11-07 2018-11-08 マルチビア インコーポレイテッド がんの処置のための腫瘍抑制因子遺伝子治療および免疫チェックポイント治療を含む組成物
EP3805376A1 (en) * 2016-01-08 2021-04-14 Replimune Limited Engineered virus
EP3419662A4 (en) * 2016-02-25 2019-09-18 Memorial Sloan Kettering Cancer Center RECOMBINANT MVA OR MVADELE3L EXPRESSING FLT3L HUMAN AND THEIR USE AS IMMUNOTHERAPEUTIC AGENTS AGAINST SOLID TUMORS
HRP20211145T1 (hr) 2016-05-30 2021-12-24 Astellas Pharma Inc. Novi genetski modificiran virus vakcinije
US20190336552A1 (en) 2016-05-30 2019-11-07 Astellas Pharma Inc. Genetically engineered vaccinia viruses
US10888594B2 (en) 2016-05-30 2021-01-12 National University Corporation Tottori University Genetically engineered vaccinia viruses
WO2018049261A1 (en) * 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
AU2017331275A1 (en) 2016-09-23 2019-05-16 Oncosec Medical Incorporated Modulating responses to checkpoint inhibitor therapy
CA3046961A1 (en) * 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
US10232053B2 (en) * 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
EP4286009A3 (en) * 2017-04-21 2024-04-03 Sillajen, Inc. Oncolytic vaccinia virus and checkpoint inhibitor combination therapy

Also Published As

Publication number Publication date
TW202027769A (zh) 2020-08-01
EP3858369A1 (en) 2021-08-04
CA3113965A1 (en) 2020-04-02
JPWO2020067085A1 (ja) 2021-08-30
BR112021005803A2 (pt) 2021-06-29
TWI824020B (zh) 2023-12-01
IL281730A (en) 2021-05-31
US20210315951A1 (en) 2021-10-14
WO2020067085A1 (ja) 2020-04-02
CN112739360A (zh) 2021-04-30
US11638730B2 (en) 2023-05-02
EP3858369A4 (en) 2022-07-20
AU2019351255A1 (en) 2021-04-29
KR20210065976A (ko) 2021-06-04
JOP20210051A1 (ar) 2021-03-17
MX2021003539A (es) 2021-05-27

Similar Documents

Publication Publication Date Title
WO2017079746A3 (en) Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
WO2015103438A3 (en) Oncolytic virus adjunct therapy with agents that increase virus infectivity
WO2014127917A8 (en) Combination of vaccination and inhibition of the pd-1 pathway
CL2015000784A1 (es) Compuestos derivados de acilaminopirimidina, inductores de interferon; composicion farmaceutica que los comprende; su uso en el tratamiento de infecciones viricas, trastornos inmunitarios, cancer y otras enfermedades.
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
WO2016025635A3 (en) Combination therapy for treating cancer
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
CA3060516A1 (en) Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
BR112017019738A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
EP3699270A4 (en) RECOMBINATED ONCOLYTIC ADENOVIRUS ISOLATED, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF RECOMBINATED ONCOLYTIC ADENOVIRUS ISOLATED IN A MEDICINAL PRODUCT FOR THE TREATMENT OF TUMOR AND / OR CANCER
SG11202103097QA (en) Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
EP3690034A4 (en) ISOLATED RECOMBINANT ONCOLYTIC SMALLPOX VIRUS, PHARMACEUTICAL COMPOSITION AND USES FOR TREATMENT OF TUMORS AND / OR CANCER
MY201105A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
SG10201809701TA (en) Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
IL267344A (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
WO2016043874A3 (en) Combination therapy for treating cancer
MX2018010709A (es) Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control.
IL267503A (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
EP3897725A4 (en) COMBINATION OF RADIOIMMUNOTHERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF CANCER
WO2015054678A3 (en) Human papilloma virus therapeutic vaccine
EP3888648A4 (en) CANCER TREATMENT BY COMBINATION OF IMMUNE CHECKPOINT INHIBITOR AND FOLFIRINOX THERAPY
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
MX2019005309A (es) Anticuerpos anti-bag3 en combinacion con inhibidores del punto de control inmunitario para uso terapeutico.